Acromegaly update

Actualización en Acromegalia

1. De Pablos P.L. Epidemiología. En: Webb S. Acromegalia. Madrid: Editorial Acción Médica; 1998. p. 9.

2. Sheaves R. A history of acromegaly. Pituitary 1999;2:7-28.

3. Alexander L, Appleton D, Halla R, Ross WM. Epidemiology of acromegaly in the New Castle region. Clin Endocrino! 1980;12:71-79.

4. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41.

5. Levy A. Monoclonality of endocrine tumours: what does it mean? Trends in Endocrinology and Metabolism 2001;12:301-7.

6. Frohman L, Kineman R. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends in Endocrinology and Metabolism 2002;13:299-303.

7. Shimon I, Melmed S. Genetic basis of endocrine disease. Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997;82:1675-81.

8. Hayward B, Barlier A, Korbonits M, Grossman A, Jacquet P, Enjalbert A, Bonthron D. Imprinting of the Gs" gene GNAS1 in the patogenesis of acromegaly. J Clin Invest 2001; 107: R31-37.

9. Drange M, Melmed S. Molecular pathogenesis of acromegaly. Pituitary 1999,2 : 43-50.

10. Drange M, Melmed S. Etiopatogenia. En: Webb S Acromegalia. Madrid: Editorial Acción Médica; 1998. p. 21-37. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current

11. treatment guidelines for acromegaly. J Clin Endocrino! Metab 1998;83: 2646-52.

12. Ben-Shlomo A, Melmed S. Acromegaly. Endocrino! Metab Clin North AM 2001;30: 565-583.
.
13. Melmed S. Acromegaly. En: Melmed S: The pituitary. Cambridge: Editorial Blackwell Science; 1995. p.413-442.

14. Gómez LA, García H. Clínica. En: Webb S: Acromegalia. Madrid: Editorial Acción Médica; 1998. p. 55-83.

15. Lucas T. Gigantismo y acromegalia. En: Jara Endocrinología. Madrid: Editorial Médica Panamericana; 2001. p. 56.

16. Melmed S. Acromegaly. En: DeGroot L, Jameson J. Endocrinology. Fourth Edition. Philadelphia: Editorial W.B.Saunders; 2001. p. 300-312.

17. Colao AM, Marzullo P, Di Somma C, Lombardi G Growth hormone and the heart. Clin Endocrinol 2001;54:137-54.

18. Renehan A, Bhaskar P, Painter J, O'Dwyer S, Haboubi N, Varma J, Ball S, Shalet S. The prevalence and characteristics of colorectal neoplasia in acromegaly J Clin Endocrinol metab 2000; 83:3417-24.

19. Kaltsas G.A, Mukherjee P, Jenkins M, Satta A, Islam N, Monson J, Besser G, Grossman A. Menstrual irregularity in women with acromegaly. J Clin Endocrino! Metab 1999; 84:2731-5.

20. Chapman IM, Hartmann MI, Straue M, Johnson MI, Velhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminiscense assays reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrino! Metab 1994; 78:1312-7.

21. Daughaday WH, Starkey RH, Saltman S, Gavin BIJR, MillsDunlap B, Heath-Monnig E. Characterization of serum growth hormone and insuline-like growth factor I in active acromegaly with minimal elevation of serum GH J Clin Endocrino! Metab 1987; 65:617-23.

22. Patel Y, Ezzat S, Chik C, Rorstad O, Serri O, Ur E, Wilkins E Guidelines for the diagnosis and treatment of acromegaly: A Canadian perpective. Clin Invest Med 2000; 23:172-87.

23. Shimon I, Cohen Z, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001;48:1239-45.

24. Biermasz N, Van Dulken H, Roelfsema F. Ten year followup results of transsphenoidal microsurgery in acromegaly. J Clin Endocrino! Metab 2000;85:4596-602.

25. Ahmed S, Elsheikh M, Stratton M, Page RC, Adams CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrino! 1999; 50:561-7.

26. Epaminonda P, Porreti S, Capiello V, Beck-Peccoz P, Faglia G, Arosio M. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol 2001;55:183-9.

27. Peacey S, Toogood A, Veldhuis J, Thorner M, Shalet S. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 2001;86:259-66.

28. Jaffe C. Reevaluation of conventional pituitary irradiation in the therapy of acromegaly. Pituitary 1999; 2:55-62.

29. Biermasz N, Van Dulken H, Roelfsema F. Long term followup results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85:2476-82.

30. Colao A, Ferone D, Maezullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518-23.

31. Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol metab 1998;82:374-8.

32. Van der Lely A, De Herder W, Lamberts S. New medical treatment for acromegaly. Pituitary 1999;2:89-92.

33. Newman C. Medical therapy for acromegaly. Endocrine Metab Clin North Am 1999;28: 171-90.

34. Ayuk J, Stewart S, Stewart P, Sheppard M. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87:4142-6.

35. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G Long term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86:2779-86.

36. Van der Lely A, Hutson K, Trainer P, Besser M, Barkan A, et al. Long term treatment of acromegaly with pegvisomat, a growth hormone receptor antagonist. Lancet 2001;358:1754-9.

37. Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Consensus. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.

38. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G; Vance LK, Von Werder K, Wass J, Guistina A. Consensus. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8.